RxDoctor Payments Data

Michelle Dedon

Family · Ludlow, MANPI 1669960274

Payments from drug & device makers

$1,324in general payments, 2019–2025

Across 41 payments — averaging $32.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$226
  • Lundbeck LLC$214
  • Mylan Specialty L.p.$160
  • Sanofi$159
  • E.r. Squibb & Sons, L.L.C.$121
  • Pfizer$103
  • plus $343 from 9 others

What the payments were for

  • Food & beverage$1,324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,324 in reported general payments places this provider in the 85th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Medicare billing

Part B allowed, 2024
$16,373
Medicare patients
200
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$37,221
JardianceEmpagliflozin14$12,958
Albuterol Sulfate HfaAlbuterol Sulfate45$1,121
Atorvastatin Calcium67$705
Pravastatin Sodium37$693
Omeprazole48$645
Fluticasone Propionate30$555
Lisinopril79$535
Levothyroxine Sodium72$535
Metoprolol Succinate36$467
Topiramate11$443
Montelukast Sodium15$425
Ropinirole Hcl11$410
Famotidine16$382
Escitalopram Oxalate16$380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$103$37,22142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,320 family providers in Massachusetts.

Other family in Ludlow

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →